Peter Lenting

Peter Lenting obtained his PhD with honours at the medical faculty of the University of Amsterdam, the Netherlands in 1996. He was appointed associate-professor of haematology at the University Medical Center in Utrecht, the Netherlands in 2000. Between 2007 and 2009, he held a position of Director of Protein & Antibody Discovery at Crucell Holland (Leiden, the Netherlands). In March 2009, he joined Inserm as Director of Research.

His research activities are mainly focussed on the Factor VIII/von Willebrand factor (FVIII/VWF) complex and the related disorders haemophilia A and von Willebrand disease. He was elected member of the council of the International Society of Thrombosis and Haemostasis (ISTH) in 2012, and chairs the ISTH-WHO-liaison committee. He is also an elected member of the council of the French Group for Thrombosis & Haemostasis (2017), and is member of the Scientific advisory board of the French Association for Haemophilia patients. In 2009, Dr. Lenting received the Prix Danièle Hermann (Foundation for Cardio-vascular Research, Institut de France) for his research activities.